Skip to main content
. 2017 Jan 25;2(5):556–560. doi: 10.1001/jamacardio.2016.5395

Figure 1. Levels of Circulating Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) and Low-Density Lipoprotein Cholesterol (LDL-C) Level.

Figure 1.

Levels of circulating PCSK9 and LDL-C over time in 138 patients in the pharmacokinetic and pharmacodynamic substudy treated with evolocumab, 140 mg every 2 weeks (A) or 420 mg monthly (B). The error bars represent the 95% CIs. The arrowheads represent administration of evolocumab.